Emularon seis ensayos objetivo utilizando seis cohortes separadas, cada una de las cuales representa una comparacin de clases de frmaco por pares: GLP-1 RA frente a inhibidores de SGLT2, GLP-1 RA frente a inhibidores de DPP4, GLP-1 RA frente a SU, inhibidores de SGLT2 frente a inhibidores de DPP4, inhibidores de SGLT2 frente a SU e inhibidores de DPP4 frente a SU
[DOI] [PMC free article] [PubMed] [Google Scholar] 53.Sikiric P., Seiwerth S., Rucman R., Turkovic B., Rokotov D., Brcic L., Sever M., Klicek R., Radic B., Drmic D., et al
A 2026 study published in The Lancet suggests that tirzepatide, a dual GLP-1 and GIP receptor agonist already approved for treatment of diabetes and obesity, could be an effective tool for fighting alcohol use disorder (AUD)
Reclassification to Category 1 means licensed compounding pharmacies can legally prepare these compounds under a physicians prescription
Focus on your own progress
L- - , ( )